Printer Friendly

MERIDIAN RELEASES FIRST INTERNALLY DEVELOPED IMMUNOCARD(R) PRODUCT

 CINCINNATI, Feb. 4 /PRNewswire/ -- Meridian Diagnostics, Inc. (NASDAQ/NMS: KITS), Cincinnati, today announced that it has received Food and Drug Administration clearance to begin marketing a new diagnostic test called ImmunoCard(R) Clostridium difficile. Clostridium difficile is a bacteria which produces a very potent toxin capable of causing serious complications to the digestive system. The disease is generally caused by an adverse reaction to antibiotic therapy. Early detection of this disease is very important and can be life saving.
 ImmunoCard is a small, credit card sized device capable of performing rapid, individual enzyme immunoassays. This device detects Clostridium difficile directly from diarrheal stool specimens in fifteen minutes with a high degree of accuracy and requires no equipment.
 The current world-wide market for Clostridium difficile products is estimated to exceed $12 million. Development of this product into the ImmunoCard format will provide the opportunity to enhance the company's position in this marketplace.
 Jerry L. Ruyan, chief executive officer said, "Because of this product's unique properties of simplicity, ease of use and accuracy, we believe it represents an opportunity to make a significant impact into the C. difficile marketplace. We believe this test has the potential to be one of the company's most important products within the next several years."
 William J. Motto, chairman of Meridian Diagnostics said, "The exciting thing about this new product opportunity is that it is the very first in a line of internally developed diagnostic products using the recently acquired ImmunoCard format. We currently have four additional products under development in the ImmunoCard format."
 Meridian Diagnostics, Inc. develops, manufactures and markets a variety of immunodiagnostic test kits, purified reagents such as antigens and monoclonal and polyclonal antibodies, and related diagnostic products. The company is a leader in the area of rapid diagnosis of infectious human diseases. All Meridian products are used outside the human body and require little or no special instrumentation or equipment. Domestic and international market segments consist of hospital, commercial and reference laboratories, and physicians' offices. The company has a leading market position in fungal serology, and is the leader in parasite and bacterial collection, preservation and transportation systems. The company's shares are traded through NASDAQ/NMS (symbol: KITS).
 -0- 2/4/93
 /CONTACT: Jerry L. Ruyan of Meridian Diagnostics, Inc., 513-271-3700/
 (KITS)


CO: Meridian Diagnostics, Inc. ST: Ohio IN: MTC SU: PDT

BM -- CL015 -- 3071 02/04/93 14:22 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1993
Words:398
Previous Article:SASI EXPANDS ITS SALES, MARKETING AND SUPPORT ORGANIZATION
Next Article:MARTIN MARIETTA WINS MAGLEV STUDY CONTRACT
Topics:


Related Articles
MERIDIAN ANNOUNCES FIRST QUARTER RESULTS
MERIDIAN RECEIVES FDA CLEARANCE TO MARKET NEW IMMUNOCARD PRODUCT TO DIAGNOSE INFECTIOUS MONONUCLEOSIS
MERIDIAN RELEASES THIRD IMMUNOCARD PRODUCT WITH TWO MORE IN DEVELOPMENT
MERIDIAN RELEASES FOURTH IMMUNOCARD PRODUCT
MERIDIAN RELEASES FIFTH IMMUNOCARD PRODUCT, A TEST TO DETECT H. PYLORI
MERIDIAN RELEASES SIXTH IMMUNOCARD PRODUCT: IMMUNOCARD CLOSTRIDIUM DIFFICILE TOXIN A
MERIDIAN APPLIES FOR A NEW WHOLE-BLOOD INDICATION FOR ITS IMMUNOCARD H. PYLORI PRODUCT
Meridian Receives FDA Clearance To Market Whole Blood Test For Stomach Ulcers
MERIDIAN BEGINS DISTRIBUTION OF RAPID TEST FOR STOMACH ULCERS.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters